Patents by Inventor Seishi Katsumata

Seishi Katsumata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10675275
    Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: June 9, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seishi Katsumata, Katsukuni Mitsui, Yuya Ezaki
  • Publication number: 20180169077
    Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.
    Type: Application
    Filed: January 8, 2016
    Publication date: June 21, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seishi KATSUMATA, Katsukuni MITSUI, Yuya EZAKI
  • Publication number: 20170119742
    Abstract: The present invention relates to a medicament for preventing and/or treating stress diseases, said medicament being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] is administered at such a specific dose that a brain TSPO occupancy requiring for expressing the pharmacological effects of the medicament can be obtained.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seishi KATSUMATA, Katsukuni MITSUI
  • Publication number: 20170059553
    Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.
    Type: Application
    Filed: February 18, 2015
    Publication date: March 2, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin Fukudo, Seishi Katsumata, Hideaki Tada, Akio Hayashi, Chie Murata
  • Patent number: 7872133
    Abstract: The present invention relates to the compound represented by formula (I) A-X—Y—Z—B??(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: January 18, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Takeshi Matsushita, Seishi Katsumata, Junichiro Manako
  • Publication number: 20080249154
    Abstract: A compound represented by formula (I) (wherein ring A is a nitrogen-containing ring which may have a substituent(s), E is a binding bond or a spacer of which main chain has an atom number of 1-8, Q is a hydrogen atom, a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s).), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. Since the compounds of the present invention represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.
    Type: Application
    Filed: December 24, 2004
    Publication date: October 9, 2008
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Seishi Katsumata, Junichiro Manako
  • Patent number: 7368444
    Abstract: The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: May 6, 2008
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako, Kazuyuki Ohmoto
  • Publication number: 20070275990
    Abstract: The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof. Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.
    Type: Application
    Filed: November 12, 2004
    Publication date: November 29, 2007
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Hiroshi Kohno, Seishi Katsumata, Junichiro Manako
  • Publication number: 20070099938
    Abstract: The compound represented by formula (I) (wherein ringA is cyclic group which may have a substituent(s), Q is alkyl which may have a substituent(s) or cyclic ring which may have a substituent(s), ringD is cyclic ring which may have a substituent(s), W is a single bond or a spacer of which main chain has an atom number of 1-4, Y is a spacer of which main chain has an atom number of 1-4.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.
    Type: Application
    Filed: October 22, 2004
    Publication date: May 3, 2007
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Seishi Katsumata, Junichiro Manako
  • Publication number: 20070027156
    Abstract: CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R1 is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.
    Type: Application
    Filed: September 8, 2004
    Publication date: February 1, 2007
    Inventors: Hisao Nakai, Tetsuji Saito, Tetsuo Obitsu, Chiaki Minamoto, Mayuki Yoshida, Akihiro Kishi, Seishi Katsumata, Hideo Katayama
  • Publication number: 20060154944
    Abstract: The present invention relates to the compound represented by formula (I) A—X—Y-Z-B??(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.
    Type: Application
    Filed: June 22, 2004
    Publication date: July 13, 2006
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Takeshi Matsushita, Seishi Katsumata, Junichiro Manako
  • Publication number: 20050101600
    Abstract: The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.
    Type: Application
    Filed: February 13, 2003
    Publication date: May 12, 2005
    Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako, Kazuyuki Ohmoto
  • Publication number: 20050009812
    Abstract: A pharmaceutical composition for the prophylaxis and/or treatment of diseases induced, exacerbated or reignited by stressors comprising the compound of formula (I) wherein all symbols have the same meanings as described in the specification, etc. as an active ingredient.
    Type: Application
    Filed: October 4, 2002
    Publication date: January 13, 2005
    Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako